The p53-p21Cip1 and p16Ink4a-Rb pathways are initially identified as tumor suppressor pathways, and p21Cip1 and p16Ink4a function as cyclin-dependent kinase (CDK) inhibitors, which block cell cycle progression. The gene discussed is CDKN2A; the disease is neoplasm.